Pub Date : 2026-01-29DOI: 10.1016/j.retram.2026.103566
Emilie Martin, Stéphane Morisset, Mohamad Sobh, Alfred Quillon, Hélène Boyer, Philippe Rey, Emmanuelle Nicolas Virelizier, Souad Assaad, Amine Belhabri, Yann Guillermin, Laure Lebras, Valérie Mialou, Jean-Paul Bourgeot, Mélinda Teyssier, Mohamed Brahimi, Soufi Osmani, Kamila Amani, Samira Bouchama, Lila Charef, Nabil Yafour, Badra Entasoltan, Anne Sophie Michallet, Mohamed-Amine Bekadja, Mauricette Michallet
Introduction: Despite numerous therapeutic advances, first line standard care for eligible multiple myeloma (MM) patients still include high-dose melphalan and autologous stem cell transplantation (ASCT).
Methods: Our study concerned MM patients who received ASCT followed or not by consolidation and maintenance, treated in two reference centers in France (Lyon n=342) and in Algeria (Oran n=452) before the daratumumab era.
Results: Despite differences in resources, we showed similar long-term Overall Survival (OS) for the two groups and similar survival for patients who did not receive any chemotherapy after ASCT for relapse. After using the instant ratio, we found a longer Time to Next Treatment for Algerian patients compared to French patients. Regarding patients who relapsed after ASCT we found a significantly better OS for French patients who received up to 3 lines of treatment after ASCT compared to Algerian patients CONCLUSION: The study of long-term overall survival of MM patients after ASCT remains very useful particularly for countries for which innovative therapies including immunotherapy are not accessible, and the differences observed during ASCT management and after relapse could point to paths for improving certain clinical situations regarding the offer of MM care in these countries.
{"title":"Real-world treatment and long-term outcomes after autologous stem cell transplantation in first line for myeloma in France and Algeria before the daratumumab era.","authors":"Emilie Martin, Stéphane Morisset, Mohamad Sobh, Alfred Quillon, Hélène Boyer, Philippe Rey, Emmanuelle Nicolas Virelizier, Souad Assaad, Amine Belhabri, Yann Guillermin, Laure Lebras, Valérie Mialou, Jean-Paul Bourgeot, Mélinda Teyssier, Mohamed Brahimi, Soufi Osmani, Kamila Amani, Samira Bouchama, Lila Charef, Nabil Yafour, Badra Entasoltan, Anne Sophie Michallet, Mohamed-Amine Bekadja, Mauricette Michallet","doi":"10.1016/j.retram.2026.103566","DOIUrl":"https://doi.org/10.1016/j.retram.2026.103566","url":null,"abstract":"<p><strong>Introduction: </strong>Despite numerous therapeutic advances, first line standard care for eligible multiple myeloma (MM) patients still include high-dose melphalan and autologous stem cell transplantation (ASCT).</p><p><strong>Methods: </strong>Our study concerned MM patients who received ASCT followed or not by consolidation and maintenance, treated in two reference centers in France (Lyon n=342) and in Algeria (Oran n=452) before the daratumumab era.</p><p><strong>Results: </strong>Despite differences in resources, we showed similar long-term Overall Survival (OS) for the two groups and similar survival for patients who did not receive any chemotherapy after ASCT for relapse. After using the instant ratio, we found a longer Time to Next Treatment for Algerian patients compared to French patients. Regarding patients who relapsed after ASCT we found a significantly better OS for French patients who received up to 3 lines of treatment after ASCT compared to Algerian patients CONCLUSION: The study of long-term overall survival of MM patients after ASCT remains very useful particularly for countries for which innovative therapies including immunotherapy are not accessible, and the differences observed during ASCT management and after relapse could point to paths for improving certain clinical situations regarding the offer of MM care in these countries.</p>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"74 1","pages":"103566"},"PeriodicalIF":3.0,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146159168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-12DOI: 10.1016/j.retram.2026.103565
Lida Aslanian-Kalkhoran, Mohammad Sadegh Soltani-Zangbar, Ali Aghebati-Maleki, Javad Ahmadian Heris, Mehdi Yousefi, Leili Aghebati-Maleki
Background: Following the confirmation of studies on the improvement of pregnancy outcomes after treatment with lymphocytes, this project aimed to assess the effectiveness of this treatment method in patients with unexplained recurrent pregnancy loss (uRPL).
Methods: After isolating B cells from 100 uRPL patients, the frequency of IL-10+B cells after treatment was measured by flow cytometry. Real-time PCR was applied to appraise the mRNA expression of microRNA and Programmed death-ligand 1(PD-L1) genes. The measurement of interleukin-10 (IL-10) secretory level in the supernatant medium was performed using the Enzyme-linked immunosorbent assay (ELISA) method.
Results: The data demonstrated that the frequency of IL-10+B cells increased after treatment with PBMCs. The expression levels of miR-10a and miR-155 were elevated in patients who received PBMCs treatments, while the levels of miR-16 and miR-21 were decreased. Furthermore, after PBMCs treatment, an increased expression level of PD-L1 was observed. The ELISA results indicated that IL-10 secretion levels increased significantly with PBMC therapy. In the group treated with PBMCs, 33 out of 50 women (66%) achieved a live birth, compared to only 15 out of 50 women (30%) in the control group.
Conclusion: In patients with uRPL, PBMCs treatment can enhance the chances of successful pregnancy by positively influencing immune regulatory factors.
{"title":"IL-10+ regulatory B lymphocytes are impacted by intradermal PBMCs therapy in patients with unexplained recurrent pregnancy loss (uRPL).","authors":"Lida Aslanian-Kalkhoran, Mohammad Sadegh Soltani-Zangbar, Ali Aghebati-Maleki, Javad Ahmadian Heris, Mehdi Yousefi, Leili Aghebati-Maleki","doi":"10.1016/j.retram.2026.103565","DOIUrl":"https://doi.org/10.1016/j.retram.2026.103565","url":null,"abstract":"<p><strong>Background: </strong>Following the confirmation of studies on the improvement of pregnancy outcomes after treatment with lymphocytes, this project aimed to assess the effectiveness of this treatment method in patients with unexplained recurrent pregnancy loss (uRPL).</p><p><strong>Methods: </strong>After isolating B cells from 100 uRPL patients, the frequency of IL-10<sup>+</sup>B cells after treatment was measured by flow cytometry. Real-time PCR was applied to appraise the mRNA expression of microRNA and Programmed death-ligand 1(PD-L1) genes. The measurement of interleukin-10 (IL-10) secretory level in the supernatant medium was performed using the Enzyme-linked immunosorbent assay (ELISA) method.</p><p><strong>Results: </strong>The data demonstrated that the frequency of IL-10<sup>+</sup>B cells increased after treatment with PBMCs. The expression levels of miR-10a and miR-155 were elevated in patients who received PBMCs treatments, while the levels of miR-16 and miR-21 were decreased. Furthermore, after PBMCs treatment, an increased expression level of PD-L1 was observed. The ELISA results indicated that IL-10 secretion levels increased significantly with PBMC therapy. In the group treated with PBMCs, 33 out of 50 women (66%) achieved a live birth, compared to only 15 out of 50 women (30%) in the control group.</p><p><strong>Conclusion: </strong>In patients with uRPL, PBMCs treatment can enhance the chances of successful pregnancy by positively influencing immune regulatory factors.</p>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"74 1","pages":"103565"},"PeriodicalIF":3.0,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146101060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.retram.2026.103564
Sha Li, Jinye Xie, Yuan Tian, Weijia Wang, Juan Wang, Xing’er Wu, Renzhou Li, Man Li, Limin Li
Objective
Reference intervals for hemoglobin fractions in neonatal cord blood have been reported; however, there is no consensus on population-specific reference intervals (RIs) and laboratory-derived clinical decision values (CDVs) to guide genetic testing. Therefore, we aimed to establish RIs for HbA, HbF, and HbA2 in neonatal cord blood using a big-data-based indirect method and to determine CDVs for neonatal β-thalassemia genetic testing.
Methods
In this retrospective study, we analyzed neonatal cord blood hemoglobin electrophoresis and β-thalassemia genetic testing data collected between January 2013 and November 2024. RIs for HbA, HbF, and HbA2 were established using an indirect method, and CDVs for β-thalassemia genetic testing were determined using receiver operating characteristic (ROC) curve analysis among neonates tested for β-thalassemia.
Results
Significant sex-related differences were observed in the RIs for neonatal cord blood hemoglobin. The RIs for HbA, HbF, and HbA2 were 7.8–29.4 %, 70.8–92.0 %, and 0–0.4 % in females and 6.9–27.3 %, 72.1–93.3 %, and 0–0.3 % in males, respectively. HbA2 was not a suitable marker for β-thalassemia genetic testing due to its extremely low levels in neonatal cord blood. The CDVs for β-thalassemia genetic testing were HbA ≤ 8.1 % and HbF ≥ 90.7 % in females and HbA ≤ 7.9 % and HbF ≥ 92.0 % in males, respectively.
Conclusion
In this study, we established population-specific RIs for neonatal cord hemoglobin and proposed CDVs indicating that β-thalassemia testing is warranted when HbF ≥ 90.7 % in females or ≥ 92.0 % in males.
{"title":"Establishing hemoglobin A, F, A2 reference intervals in neonatal cord blood and clinical decision values for β-thalassemia genetic testing","authors":"Sha Li, Jinye Xie, Yuan Tian, Weijia Wang, Juan Wang, Xing’er Wu, Renzhou Li, Man Li, Limin Li","doi":"10.1016/j.retram.2026.103564","DOIUrl":"10.1016/j.retram.2026.103564","url":null,"abstract":"<div><h3>Objective</h3><div>Reference intervals for hemoglobin fractions in neonatal cord blood have been reported; however, there is no consensus on population-specific reference intervals (RIs) and laboratory-derived clinical decision values (CDVs) to guide genetic testing. Therefore, we aimed to establish RIs for HbA, HbF, and HbA2 in neonatal cord blood using a big-data-based indirect method and to determine CDVs for neonatal β-thalassemia genetic testing.</div></div><div><h3>Methods</h3><div>In this retrospective study, we analyzed neonatal cord blood hemoglobin electrophoresis and β-thalassemia genetic testing data collected between January 2013 and November 2024. RIs for HbA, HbF, and HbA2 were established using an indirect method, and CDVs for β-thalassemia genetic testing were determined using receiver operating characteristic (ROC) curve analysis among neonates tested for β-thalassemia.</div></div><div><h3>Results</h3><div>Significant sex-related differences were observed in the RIs for neonatal cord blood hemoglobin. The RIs for HbA, HbF, and HbA2 were 7.8–29.4 %, 70.8–92.0 %, and 0–0.4 % in females and 6.9–27.3 %, 72.1–93.3 %, and 0–0.3 % in males, respectively. HbA2 was not a suitable marker for β-thalassemia genetic testing due to its extremely low levels in neonatal cord blood. The CDVs for β-thalassemia genetic testing were HbA ≤ 8.1 % and HbF ≥ 90.7 % in females and HbA ≤ 7.9 % and HbF ≥ 92.0 % in males, respectively.</div></div><div><h3>Conclusion</h3><div>In this study, we established population-specific RIs for neonatal cord hemoglobin and proposed CDVs indicating that β-thalassemia testing is warranted when HbF ≥ 90.7 % in females or ≥ 92.0 % in males.</div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"74 1","pages":"Article 103564"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145968070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-17DOI: 10.1016/j.retram.2025.103563
Hossein Salehi-Shadkami , Mosslim Sedghi , Shima Tavoosi , Masoumeh Alimohammadi , Reza Alimohammadi , Maryam Barkhordar , Ahmadreza Mofayezi , Mohammad Sadra Modaresi , Mohammad Vaezi , Somaye Dehghanizadeh , Mohammad Ahmadvand , Vahid Khoddami
Chimeric antigen receptor natural killer (CAR-NK) cell therapy is recognized as a promising modality for the treatment of hematologic malignancies, particularly B-cell malignancies. In this study, we developed “off-the-shelf” anti-CD19 CAR-NK cells using anti-CD19 CAR mRNAs formulated in proprietary ionizable lipid nanoparticles (LNPs). The efficiency of mRNA-LNP delivery into umbilical cord blood (UCB)-derived NK cells and primary T cells was evaluated in an in vitro setting, demonstrating superior delivery efficiency in NK cells. Further investigation showed a probable role for an endocytic mechanism, macropinocytosis, in efficient transfection of NK cells with LNPs. Nevertheless, CAR-NK cells generated through this mRNA-LNP platform exhibited significantly enhanced cytotoxicity against CD19+ target cells, such as EGFP+Raji stable cell line and primary malignant B cells derived from refractory/relapsed B-cell acute lymphoblastic leukemia (B-ALL) patients. These findings highlight the promise of the mRNA-LNP platform in advancing CAR-NK therapies against B-cell malignancies.
嵌合抗原受体自然杀伤（CAR-NK）细胞疗法被认为是治疗血液系统恶性肿瘤，特别是b细胞恶性肿瘤的一种有前途的方式。在这项研究中，我们使用专有的可电离脂质纳米颗粒（LNPs）配制的抗cd19 CAR- nk mrna开发了“现成的”抗cd19 CAR- nk细胞。在体外环境中评估mRNA-LNP在脐带血（UCB）来源的NK细胞和原代T细胞中的递送效率，显示出在NK细胞中的优越递送效率。进一步的研究表明，在LNPs有效转染NK细胞中，内吞机制巨噬作用可能起作用。然而，通过mRNA-LNP平台生成的CAR-NK细胞对CD19+靶细胞（如EGFP+Raji稳定细胞系和来自难治性/复发性B细胞急性淋巴细胞白血病（B- all）患者的原发性恶性B细胞）表现出显著增强的细胞毒性。这些发现突出了mRNA-LNP平台在推进CAR-NK治疗b细胞恶性肿瘤方面的前景。
{"title":"Lipid nanoparticle mediated delivery of Anti-CD19 CAR mRNA to umbilical blood cord NK cells for targeting CD19⁺ primary B-ALL cells","authors":"Hossein Salehi-Shadkami , Mosslim Sedghi , Shima Tavoosi , Masoumeh Alimohammadi , Reza Alimohammadi , Maryam Barkhordar , Ahmadreza Mofayezi , Mohammad Sadra Modaresi , Mohammad Vaezi , Somaye Dehghanizadeh , Mohammad Ahmadvand , Vahid Khoddami","doi":"10.1016/j.retram.2025.103563","DOIUrl":"10.1016/j.retram.2025.103563","url":null,"abstract":"<div><div>Chimeric antigen receptor natural killer (CAR-NK) cell therapy is recognized as a promising modality for the treatment of hematologic malignancies, particularly B-cell malignancies. In this study, we developed “off-the-shelf” anti-CD19 CAR-NK cells using anti-CD19 CAR mRNAs formulated in proprietary ionizable lipid nanoparticles (LNPs). The efficiency of mRNA-LNP delivery into umbilical cord blood (UCB)-derived NK cells and primary T cells was evaluated in an in vitro setting, demonstrating superior delivery efficiency in NK cells. Further investigation showed a probable role for an endocytic mechanism, macropinocytosis, in efficient transfection of NK cells with LNPs. Nevertheless, CAR-NK cells generated through this mRNA-LNP platform exhibited significantly enhanced cytotoxicity against CD19<sup>+</sup> target cells, such as EGFP<sup>+</sup>Raji stable cell line and primary malignant B cells derived from refractory/relapsed B-cell acute lymphoblastic leukemia (B-ALL) patients. These findings highlight the promise of the mRNA-LNP platform in advancing CAR-NK therapies against B-cell malignancies.</div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"74 1","pages":"Article 103563"},"PeriodicalIF":3.0,"publicationDate":"2025-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145806490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chimeric Antigen Receptor (CAR) T cell therapy is a novel cum innovative treatment for cancer patients, especially the ones dealing with blood cancers. However, solid tumours remain an area where this therapy is not so effective. The challenges are antigen heterogeneity, immunosuppressive tumour microenvironment, and some unaddressed serious side effects. This study details how different immunotherapeutic approaches can be used in synergy with each other to augment efficacy of CAR-T cell-based therapy and to minimize its limitations as a standalone therapy. Our review looks at how immune checkpoint inhibitors (ICIs), cytokine-based approaches, hematopoietic stem cell transplantation (HSCT), cancer vaccines, oncolytic viruses, monoclonal antibodies, NK cell therapy, tumour-infiltrating lymphocytes, bispecific T-cell engagers (BiTEs), and oncolytic viruses (OVs) could be utilized together with CAR-T cell therapy. Reducing repressive cell populations and improving antigen presentation helps OVs modify the TME, enabling better CAR-T cell penetration and persistence. Similar to this, BiTEs deal with issues of antigen loss and relapse by increasing the number of cells that target antigens and bringing in bystander T-cells. Moreover, cytokine co-delivery and changes inside cells show promise in lowering systemic toxicity and increasing continuous CAR-T activation. Early-stage clinical trials and preclinical studies show that these combinatorial strategies may work, but there are still issues like dose-dependent toxicity, exact treatment timing, and delivery restrictions. This review highlights generally the possibilities of combinational techniques to greatly increase the efficacy and safety profile of CAR-T cell treatments, thus providing insightful information for next studies and clinical uses in cancer immunotherapy.
{"title":"Integrating CAR-T cells with other immunotherapies for improved efficacy in cancer patients","authors":"Gagandeep Singh , Lata Kumari , Dipansh Katoch , Arshiya Sood , Neelam Thakur , Kaalindi Singh , Umesh Kumar","doi":"10.1016/j.retram.2025.103562","DOIUrl":"10.1016/j.retram.2025.103562","url":null,"abstract":"<div><div>Chimeric Antigen Receptor (CAR) T cell therapy is a novel cum innovative treatment for cancer patients, especially the ones dealing with blood cancers. However, solid tumours remain an area where this therapy is not so effective. The challenges are antigen heterogeneity, immunosuppressive tumour microenvironment, and some unaddressed serious side effects. This study details how different immunotherapeutic approaches can be used in synergy with each other to augment efficacy of CAR-T cell-based therapy and to minimize its limitations as a standalone therapy. Our review looks at how immune checkpoint inhibitors (ICIs), cytokine-based approaches, hematopoietic stem cell transplantation (HSCT), cancer vaccines, oncolytic viruses, monoclonal antibodies, NK cell therapy, tumour-infiltrating lymphocytes, bispecific T-cell engagers (BiTEs), and oncolytic viruses (OVs) could be utilized together with CAR-T cell therapy. Reducing repressive cell populations and improving antigen presentation helps OVs modify the TME, enabling better CAR-T cell penetration and persistence. Similar to this, BiTEs deal with issues of antigen loss and relapse by increasing the number of cells that target antigens and bringing in bystander T-cells. Moreover, cytokine co-delivery and changes inside cells show promise in lowering systemic toxicity and increasing continuous CAR-T activation. Early-stage clinical trials and preclinical studies show that these combinatorial strategies may work, but there are still issues like dose-dependent toxicity, exact treatment timing, and delivery restrictions. This review highlights generally the possibilities of combinational techniques to greatly increase the efficacy and safety profile of CAR-T cell treatments, thus providing insightful information for next studies and clinical uses in cancer immunotherapy.</div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"74 1","pages":"Article 103562"},"PeriodicalIF":3.0,"publicationDate":"2025-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145822003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-15DOI: 10.1016/j.retram.2025.103561
Ali G. Alkhathami , Abdulrahman T. Ahmed , Ahmed Hussein , Roopashree R , Prakhar Tomar , Hussein Riyadh Abdul Kareem Al-Hetty , Rajashree Panigrahi , Ashish Singh Chauhan , Fathi Jihad Hammady , Salah Abdulhadi Salih
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) represents a significant advancement in breast cancer therapy by enhancing drug delivery and minimizing solvent-related toxicity. Utilizing albumin-mediated transcytosis, nab-paclitaxel achieves superior intratumoral accumulation while eliminating hypersensitivity reactions linked to solvent-based taxanes. Clinical trials in metastatic breast cancer have demonstrated higher response rates and improved tolerability compared with conventional paclitaxel, especially in HER2-negative and triple-negative subtypes. In neoadjuvant settings, nab-paclitaxel-based regimens yield higher pCR rates and exhibit synergistic efficacy when combined with carboplatin, anthracyclines, or immune checkpoint inhibitors. Safety analyses show a favorable profile with reduced myelosuppression but an increased risk of peripheral neuropathy in certain populations. Additionally, nab-paclitaxel has been effectively incorporated into immunotherapy regimens for TNBC and HER2-targeted strategies in HER2-positive disease. Pharmacokinetic studies reveal improved tissue distribution and higher unbound paclitaxel exposure compared to solvent-based formulations. Overall, nab-paclitaxel offers distinct therapeutic advantages in terms of efficacy, safety, and tumor targeting, representing a major step forward in overcoming resistance and optimizing breast cancer treatment.
{"title":"Nanoparticle albumin-bound paclitaxel (nab-Paclitaxel): Bridging pharmacology and translational medicine in breast cancer","authors":"Ali G. Alkhathami , Abdulrahman T. Ahmed , Ahmed Hussein , Roopashree R , Prakhar Tomar , Hussein Riyadh Abdul Kareem Al-Hetty , Rajashree Panigrahi , Ashish Singh Chauhan , Fathi Jihad Hammady , Salah Abdulhadi Salih","doi":"10.1016/j.retram.2025.103561","DOIUrl":"10.1016/j.retram.2025.103561","url":null,"abstract":"<div><div>Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) represents a significant advancement in breast cancer therapy by enhancing drug delivery and minimizing solvent-related toxicity. Utilizing albumin-mediated transcytosis, nab-paclitaxel achieves superior intratumoral accumulation while eliminating hypersensitivity reactions linked to solvent-based taxanes. Clinical trials in metastatic breast cancer have demonstrated higher response rates and improved tolerability compared with conventional paclitaxel, especially in HER2-negative and triple-negative subtypes. In neoadjuvant settings, nab-paclitaxel-based regimens yield higher pCR rates and exhibit synergistic efficacy when combined with carboplatin, anthracyclines, or immune checkpoint inhibitors. Safety analyses show a favorable profile with reduced myelosuppression but an increased risk of peripheral neuropathy in certain populations. Additionally, nab-paclitaxel has been effectively incorporated into immunotherapy regimens for TNBC and HER2-targeted strategies in HER2-positive disease. Pharmacokinetic studies reveal improved tissue distribution and higher unbound paclitaxel exposure compared to solvent-based formulations. Overall, nab-paclitaxel offers distinct therapeutic advantages in terms of efficacy, safety, and tumor targeting, representing a major step forward in overcoming resistance and optimizing breast cancer treatment.</div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"74 1","pages":"Article 103561"},"PeriodicalIF":3.0,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145835323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-07DOI: 10.1016/j.retram.2025.103560
David B. Olawade , Yinka Julianah Adeniji , Faithful A. Olatunbosun , Eghosasere Egbon , Aanuoluwapo Clement David-Olawade
Anemia affects over 1.6 billion people globally, representing a significant public health challenge, particularly in low- and middle-income countries where traditional diagnostic methods face barriers including invasive procedures, skilled personnel requirements, and inadequate laboratory infrastructure. Artificial intelligence (AI) has emerged as a promising technology offering non-invasive, rapid, and cost-effective solutions for anemia detection and management. This narrative review synthesises current literature on AI applications in anemia screening, diagnosis, and clinical management, examining methodologies, performance metrics, implementation challenges, and future research directions. We conducted a comprehensive narrative synthesis informed by systematic search principles, searching PubMed, IEEE Xplore, Scopus, and Web of Science databases with additional hand-searching and expert consultation. AI models demonstrate variable accuracy in anemia detection across diverse data sources, with performance ranging from 75–97 % AUC depending on methodology and validation approaches. Machine learning algorithms such as support vector machines, convolutional neural networks, and random forests show potential for achieving performance comparable to standard blood tests in controlled research settings. Smartphone-integrated applications and point-of-care systems show particular promise for resource-limited settings, though real-world validation remains limited. While AI shows significant potential for enhancing accessibility and diagnostic efficiency in anemia care, critical challenges including data standardisation, algorithmic bias, regulatory compliance, clinical validation in diverse populations, and deployment equity in low- and middle-income countries require urgent attention to ensure equitable implementation and clinical adoption.
贫血影响全球超过16亿人，是一项重大的公共卫生挑战，特别是在传统诊断方法面临包括侵入性手术、熟练人员需求和实验室基础设施不足等障碍的低收入和中等收入国家。人工智能（AI）已经成为一种有前途的技术，为贫血的检测和管理提供了非侵入性、快速和经济的解决方案。本文综述了人工智能在贫血筛查、诊断和临床管理、检查方法、绩效指标、实施挑战和未来研究方向等方面的应用。我们根据系统的检索原则进行了全面的叙述综合，检索了PubMed、IEEE Xplore、Scopus和Web of Science数据库，并进行了额外的手工检索和专家咨询。人工智能模型在不同数据源的贫血检测中显示出不同的准确性，根据方法和验证方法的不同，其性能在75- 97%的AUC之间。支持向量机、卷积神经网络和随机森林等机器学习算法显示出在受控研究环境中实现与标准血液测试相当的性能的潜力。智能手机集成应用程序和护理点系统在资源有限的环境中显示出特别的前景，尽管实际验证仍然有限。虽然人工智能在提高贫血护理的可及性和诊断效率方面显示出巨大潜力，但迫切需要关注包括数据标准化、算法偏差、法规遵从性、不同人群的临床验证以及低收入和中等收入国家部署公平性在内的关键挑战，以确保公平实施和临床采用。
{"title":"Artificial intelligence for anemia screening, diagnosis, and management","authors":"David B. Olawade , Yinka Julianah Adeniji , Faithful A. Olatunbosun , Eghosasere Egbon , Aanuoluwapo Clement David-Olawade","doi":"10.1016/j.retram.2025.103560","DOIUrl":"10.1016/j.retram.2025.103560","url":null,"abstract":"<div><div>Anemia affects over 1.6 billion people globally, representing a significant public health challenge, particularly in low- and middle-income countries where traditional diagnostic methods face barriers including invasive procedures, skilled personnel requirements, and inadequate laboratory infrastructure. Artificial intelligence (AI) has emerged as a promising technology offering non-invasive, rapid, and cost-effective solutions for anemia detection and management. This narrative review synthesises current literature on AI applications in anemia screening, diagnosis, and clinical management, examining methodologies, performance metrics, implementation challenges, and future research directions. We conducted a comprehensive narrative synthesis informed by systematic search principles, searching PubMed, IEEE Xplore, Scopus, and Web of Science databases with additional hand-searching and expert consultation. AI models demonstrate variable accuracy in anemia detection across diverse data sources, with performance ranging from 75–97 % AUC depending on methodology and validation approaches. Machine learning algorithms such as support vector machines, convolutional neural networks, and random forests show potential for achieving performance comparable to standard blood tests in controlled research settings. Smartphone-integrated applications and point-of-care systems show particular promise for resource-limited settings, though real-world validation remains limited. While AI shows significant potential for enhancing accessibility and diagnostic efficiency in anemia care, critical challenges including data standardisation, algorithmic bias, regulatory compliance, clinical validation in diverse populations, and deployment equity in low- and middle-income countries require urgent attention to ensure equitable implementation and clinical adoption.</div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"74 1","pages":"Article 103560"},"PeriodicalIF":3.0,"publicationDate":"2025-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145769976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-04DOI: 10.1016/j.retram.2025.103558
Michal Ordak
{"title":"Corrigendum to “AI-assisted statistical review of 100 oncology research articles: compliance with SAMPL guidelines” [Current Research in Translational Medicine 73 (2025) 103544]","authors":"Michal Ordak","doi":"10.1016/j.retram.2025.103558","DOIUrl":"10.1016/j.retram.2025.103558","url":null,"abstract":"","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"74 1","pages":"Article 103558"},"PeriodicalIF":3.0,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145688733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-02DOI: 10.1016/j.retram.2025.103559
Turkan Aliyeva , Haroon Alamy , Feras Ahmad Ibrahim Ahmad , Julia Natche , Hafiz Shah , Vrushali Shelar , Huu Than Huynh , Imane El Amri
Background
Treatment of transplant-ineligible newly diagnosed multiple myeloma (TIE-NDMM) remains challenging due to age, frailty, and comorbidities. Anti-CD38 monoclonal antibodies, particularly daratumumab, have emerged as promising additions to frontline regimens. However, the long-term outcomes of these therapies are still uncertain. This systematic review and meta-analysis aimed to compare the survival outcome of anti-CD38 antibodies in TIE-NDMM patients.
Methods
We systematically searched PubMed, Embase, and Cochrane Library databases for randomized controlled trials (RCTs) published up to April 2025 comparing anti-CD38 mAbs based regimens versus standard therapy in transplant-ineligible NDMM patients. A random-effects model was used to calculate pooled hazard ratios (HRs) with 95 % confidence intervals (CIs).
Results
A total of six RCTs with 2,625 patients were included in the analysis. Of these, 1,390 (52.9 %) patients received anti-CD38-based regimens. The follow-up duration varied from 41.2 to 86.7 months across the studies. Compared to standard therapy, anti-CD38-based regimens significantly improved both overall survival (OS) (HR 0.70; 95 % CI 0.58–0.84; p=0.0002; I² = 46 %) and progression-free survival (PFS) (HR 0.57; 95 % CI 0.51–0.65; p < 0.00001; I² = 15 %). The pooled results demonstrated that non-frail patients had a longer PFS than frail patients (HR = 0.46; 95 % CI, 0.34–0.63 and HR = 0.55; 95 % CI, 0.45–0.67, respectively), although the difference between the subgroups was not statistically significant (p = 0.36).
Conclusion
In transplant-ineligible NDMM patients, the addition of anti-CD38 monoclonal antibodies to standard regimens significantly improves clinical outcomes. These findings support the integration of anti-CD38 therapy into first-line treatment for this vulnerable patient population.
背景：由于年龄、虚弱和合并症，新诊断的不适合移植的多发性骨髓瘤（TIE-NDMM）的治疗仍然具有挑战性。抗cd38单克隆抗体，特别是达拉单抗，已经成为一线治疗方案中有希望的补充。然而，这些疗法的长期效果仍不确定。本系统综述和荟萃分析旨在比较TIE-NDMM患者中抗cd38抗体的生存结局。方法：我们系统地检索PubMed、Embase和Cochrane图书馆数据库，检索截至2025年4月发表的随机对照试验（rct），比较基于抗cd38单抗的方案与标准治疗在不适合移植的NDMM患者中的效果。采用随机效应模型计算95%置信区间（ci）的合并风险比（hr）。结果共纳入6项随机对照试验，共纳入2625例患者。其中，1390例（52.9%）患者接受了基于抗cd38的治疗方案。这些研究的随访时间从41.2个月到86.7个月不等。与标准治疗相比，基于抗cd38的方案显著改善了总生存期（OS） （HR 0.70; 95% CI 0.58-0.84; p=0.0002; I²= 46%）和无进展生存期（PFS） （HR 0.57; 95% CI 0.51-0.65; p < 0.00001; I²= 15%）。合并结果显示，非体弱患者的PFS较体弱患者长（HR = 0.46, 95% CI分别为0.34-0.63和HR = 0.55, 95% CI分别为0.45-0.67），但亚组间差异无统计学意义（p = 0.36）。结论对于不适合移植的NDMM患者，在标准方案中加入抗cd38单克隆抗体可显著改善临床预后。这些发现支持将抗cd38疗法整合到这一弱势患者群体的一线治疗中。
{"title":"The efficacy and safety of anti-CD38 monoclonal antibodies in transplant-ineligible newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials","authors":"Turkan Aliyeva , Haroon Alamy , Feras Ahmad Ibrahim Ahmad , Julia Natche , Hafiz Shah , Vrushali Shelar , Huu Than Huynh , Imane El Amri","doi":"10.1016/j.retram.2025.103559","DOIUrl":"10.1016/j.retram.2025.103559","url":null,"abstract":"<div><h3>Background</h3><div>Treatment of transplant-ineligible newly diagnosed multiple myeloma (TIE-NDMM) remains challenging due to age, frailty, and comorbidities. Anti-CD38 monoclonal antibodies, particularly daratumumab, have emerged as promising additions to frontline regimens. However, the long-term outcomes of these therapies are still uncertain. This systematic review and meta-analysis aimed to compare the survival outcome of anti-CD38 antibodies in TIE-NDMM patients.</div></div><div><h3>Methods</h3><div>We systematically searched PubMed, Embase, and Cochrane Library databases for randomized controlled trials (RCTs) published up to April 2025 comparing anti-CD38 mAbs based regimens versus standard therapy in transplant-ineligible NDMM patients. A random-effects model was used to calculate pooled hazard ratios (HRs) with 95 % confidence intervals (CIs).</div></div><div><h3>Results</h3><div>A total of six RCTs with 2,625 patients were included in the analysis. Of these, 1,390 (52.9 %) patients received anti-CD38-based regimens. The follow-up duration varied from 41.2 to 86.7 months across the studies. Compared to standard therapy, anti-CD38-based regimens significantly improved both overall survival (OS) (HR 0.70; 95 % CI 0.58–0.84; p=0.0002; I² = 46 %) and progression-free survival (PFS) (HR 0.57; 95 % CI 0.51–0.65; p < 0.00001; I² = 15 %). The pooled results demonstrated that non-frail patients had a longer PFS than frail patients (HR = 0.46; 95 % CI, 0.34–0.63 and HR = 0.55; 95 % CI, 0.45–0.67, respectively), although the difference between the subgroups was not statistically significant (p = 0.36).</div></div><div><h3>Conclusion</h3><div>In transplant-ineligible NDMM patients, the addition of anti-CD38 monoclonal antibodies to standard regimens significantly improves clinical outcomes. These findings support the integration of anti-CD38 therapy into first-line treatment for this vulnerable patient population<strong>.</strong></div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"74 1","pages":"Article 103559"},"PeriodicalIF":3.0,"publicationDate":"2025-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145736905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-07-30DOI: 10.1016/j.retram.2025.103533
Mahmoud I Elbadry, Mohamed Mabed
VEXAS syndrome (vacuoles, E1 enzyme, X-linked alongside autoinflammatory and somatic) is a severe aggressive inflammation disorder arising in adults that results from acquired changes to the UBA1 gene. These genetic alterations lead to widespread chronic systemic inflammation, prominent features of clonal hematopoiesis, and worsening cytopenic decays alongside hematological malignancies. The grim prognosis includes survival-seeking patients facing life-threatening infections, bone marrow failure or thrombotic complications with only 76 % three-year survival rate. It mainly occurs in older men but rare cases in women stem from atypical patterns of X-chromosome inactivation. This syndrome shares characteristics with autoimmune disorders like relapsing polychondritis and blood disorders predominantly myelodysplastic syndromes. Diagnosis requires UBA1 genetic analysis and bone marrow examination which shows characteristic vacuolization in myeloid and erythroid progenitors. Current therapeutic approaches concentrate on fighting inflammation alongside supportive therapy. This includes infection control, transfusion administration, hypomethylating agents such as azacitidine, which provide the dual benefit of reducing mutant clones alongside inflammation, as well as immunosuppressive drugs, steroids, and Janus Kinase (JAK) inhibitors. Even though allogeneic hematopoietic stem cell transplantation (HSCT) remains the sole option for a cure, its extensive toxicity limits widespread application. Some investigational therapies targeting specific pathways show promise, particularly nucleotide-binding domain, Leucine-rich Repeat-containing family, pyrin domain containing 3 (NLRP3) inflammasome blockers (IL-1β/IL-6 inhibitors) and proteasome inhibitors like bortezomib (Bortezomib), which exploit the proteostasis defects in UBA1-mutated cells. Core obstacles still lie in the absence of a standardized treatment paradigm due to gaps in genotype-phenotype expression and variability, alongside insufficient biomarkers able to guide therapy selection and directed personalized therapeutic interventions. This review highlights the curative strategies, therapeutic challenges, and advancements in VEXAS syndrome, underscoring the urgent need for targeted strategies to improve the patient outcomes.
{"title":"Bone marrow vacuolization to curative strategies: Evolving paradigms in VEXAS syndrome management.","authors":"Mahmoud I Elbadry, Mohamed Mabed","doi":"10.1016/j.retram.2025.103533","DOIUrl":"10.1016/j.retram.2025.103533","url":null,"abstract":"<p><p>VEXAS syndrome (vacuoles, E1 enzyme, X-linked alongside autoinflammatory and somatic) is a severe aggressive inflammation disorder arising in adults that results from acquired changes to the UBA1 gene. These genetic alterations lead to widespread chronic systemic inflammation, prominent features of clonal hematopoiesis, and worsening cytopenic decays alongside hematological malignancies. The grim prognosis includes survival-seeking patients facing life-threatening infections, bone marrow failure or thrombotic complications with only 76 % three-year survival rate. It mainly occurs in older men but rare cases in women stem from atypical patterns of X-chromosome inactivation. This syndrome shares characteristics with autoimmune disorders like relapsing polychondritis and blood disorders predominantly myelodysplastic syndromes. Diagnosis requires UBA1 genetic analysis and bone marrow examination which shows characteristic vacuolization in myeloid and erythroid progenitors. Current therapeutic approaches concentrate on fighting inflammation alongside supportive therapy. This includes infection control, transfusion administration, hypomethylating agents such as azacitidine, which provide the dual benefit of reducing mutant clones alongside inflammation, as well as immunosuppressive drugs, steroids, and Janus Kinase (JAK) inhibitors. Even though allogeneic hematopoietic stem cell transplantation (HSCT) remains the sole option for a cure, its extensive toxicity limits widespread application. Some investigational therapies targeting specific pathways show promise, particularly nucleotide-binding domain, Leucine-rich Repeat-containing family, pyrin domain containing 3 (NLRP3) inflammasome blockers (IL-1β/IL-6 inhibitors) and proteasome inhibitors like bortezomib (Bortezomib), which exploit the proteostasis defects in UBA1-mutated cells. Core obstacles still lie in the absence of a standardized treatment paradigm due to gaps in genotype-phenotype expression and variability, alongside insufficient biomarkers able to guide therapy selection and directed personalized therapeutic interventions. This review highlights the curative strategies, therapeutic challenges, and advancements in VEXAS syndrome, underscoring the urgent need for targeted strategies to improve the patient outcomes.</p>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"73 4","pages":"103533"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144818245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号